This guide provides clinical practice-based information on the use of buprenorphine in the...
drugfree
What Do We Know About “Gaming Disorder”?
Video game playing is now one of the most popular hobbies across sex and age groups, but a small...
Taking Action to Break Language Barriers
The Addiction Policy Forum released prevention resources translated into 12 languages to help...
Key Takeaways from Rx Summit 2023
This summit is the largest, most influential annual event addressing the opioid and addiction...
Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine — United States, January 2019–June 2022
The Centers for Disease Control and Prevention (CDC) published a new report, Illicitly...
An Early Look at State Opioid Settlement Spending Decisions – NASHP
This issue brief provides an overview of published statewide opioid settlement spending plans and...
The ASAM Criteria 4th Edition Webinar Handout
The ASAM Criteria 4th Edition Webinar Handout
Addressing Substance Use and Social Needs of People of Color with Substance Use Disorders
This brief by the US Health and Human Services Office of Minority Health and the Office of the...
Substance Use Among Asian American Adults in 2016–2020: A Difference-in-Difference Analysis of a National Survey on Drug Use and Health Data
This study compares substance use among Asian American adults in 2020, when anti-Asian violence...
Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl
This guide provides clinical practice-based information on the use of buprenorphine in the...
Addiction Treatment Medicine Is Vastly Underprescribed, Especially by Race, Study Finds
This article from The New York Times discusses results of a study of rates of prescribed addiction...
Presentation Slides – Zeroing in on Xylazine
These presentation slides summarize trends of xylazine in U.S. illicit drug supply, describe...